Control Crohn Safe Trial

  • End date
    Sep 30, 2024
  • participants needed
  • sponsor
    Maastricht University Medical Center
Updated on 30 May 2021
combination therapy
monoclonal antibodies
chronic disease
tumor necrosis factor
crohn's disease
mucosal inflammation


Crohn's disease (CD) is a chronic disease with a heterogeneous clinical presentation, relapse rate and treatment response. Insufficient control of mucosal inflammation results in irreversible bowel damage and complications and at present no markers are available to predict such a complicated disease course at diagnosis. Therefore, to prevent overtreatment of low risk patients, step-up treatment with subsequent introduction of corticosteroids, thiopurines maintenance and TNF-blockers if a previous category fails is standard care. Combination treatment with thiopurines and a TNF-blocker is more effective than monotherapy but associated with a higher risk for infectious complications. Landmark studies convincingly showed an improved long-term outcome if the TNF-blocker infliximab is introduced early after diagnosis. The standard step-care approach thus prolongs steroid exposure and delays start of disease modifying biologicals in high risks patients. Given the higher efficacy of combination therapy with a thiopurine of infliximab and potential allergic reactions and lower response rates after re-initiation of this chimeric biological, temporary monotherapy with this TNF-blocker has not been studied as first line treatment before. Adalimumab is a humanised monoclonal antibody and subsequently, combination therapy of adalimumab + thiopurines has only a marginal effect on anti-drug anti-body formation. Furthermore, combination therapy with adalimumab does not enhance the clinical response. Therefore, periodic treatment with adalimumab in combination with close monitoring after drug-discontinuation, in newly diagnosed CD might improve outcome, reduce drug-related side effects while still preventing overtreatment.

The aim of this study is to compare the long-term efficacy and safety of periodic adalimumab as initial treatment in newly diagnosed CD patients compared to standard step-care with corticosteroid/budesonide as the initial treatment

Condition Inflammatory Bowel Disease, Crohn's Disease (Pediatric), Intestinal Diseases, Crohn's Disease, inflammatory bowel diseases, Bowel Dysfunction, Gastroenteritis, crohns disease, Inflammatory bowel disease
Treatment Adalimumab, standard step-up care
Clinical Study IdentifierNCT03917303
SponsorMaastricht University Medical Center
Last Modified on30 May 2021


Yes No Not Sure

Inclusion Criteria

Newly diagnosed CD patients or CD patients with a flare, visiting the outpatient clinic or endoscopy ward of the participating centres
CD diagnosis according to ECCO-guidelines + complete ileo-colonoscopy + complete small bowel imaging at diagnosis (MRI or CT-enterography )
Nave to thiopurines and biologicals
Sufficient knowledge of Dutch language
years old 70 years old
Smartphone with internet access
Use of myIBDcoach or willingness to start using myIBDcoach

Exclusion Criteria

Malignancy in 5 years before treatment. Exception is adequately treated non-melanoma skin cancer
Use of prednisone in the year before screening (excluding prednisone used as bridging before the start of study medication)
Use of budesonide (6 mg daily) for a duration longer than 3 months in the year before screening
Severe disease requiring hospitalisation at screening
Contra-indication for TNF-blockers or immunosuppressive agents
Active perianal fistula at screening
Patients with short bowel syndrome or an ostomy
Contra-indication for MRI- and CT-enterography
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note